| Code | CSB-RA013510MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to MG-013, specifically designed to target MASP2 (Mannan-binding lectin serine protease 2), a critical effector enzyme in the lectin pathway of complement activation. MASP2 functions as the primary activating protease that cleaves complement components C4 and C2, initiating the downstream complement cascade. This protein plays a significant role in innate immunity and has been implicated in various pathological conditions, including ischemia-reperfusion injury, thrombotic microangiopathies, age-related macular degeneration, and transplant rejection. Dysregulated MASP2 activity has also been associated with inflammatory disorders and autoimmune diseases where excessive complement activation contributes to tissue damage.
The reference antibody MG-013 has been utilized in complement research to investigate lectin pathway mechanisms and evaluate therapeutic strategies for complement-mediated disorders. This biosimilar provides researchers with a reliable tool for studying MASP2 biology, exploring complement pathway regulation, and investigating potential therapeutic interventions in diseases characterized by aberrant lectin pathway activation. It serves as a valuable reagent for advancing understanding of complement-mediated pathophysiology and developing novel therapeutic approaches.
There are currently no reviews for this product.